By using wearable devices to monitor and record the physiological data changes and health outcomes (incidence and severity of high-altitude illnesses) of high-altitude migrants at different stages (pre-entry, acute/chronic high-altitude phases, and de-acclimatization phase), and referencing previous cohort studies on high-altitude populations, the study aims to provide a basis for developing personalized health assessment protocols for high-altitude migrants. The formulated assessment protocols and standards will then be validated.
Men and women aged ≥18;
Those living in plains and preparing to move to the plateau for a short-term or medium-term period;
Can understand the research requirements and be willing to sign a written informed consent form (ICF).
Past history of contraindicated plateau travel: such as advanced COPD (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced cystic fibrosis (FEV₁<30% of the expected value or requires continuous oxygen therapy), advanced restricted pulmonary disease (FEV₁<50% of the expected value or requires continuous oxygen therapy), decompensated heart failure, high-risk pregnancy, myocardial infarction or stroke occurred within 90 days, poorly controlled epilepsy, pulmonary hypertension (PASP>90mmHg), sickle cell anemia, unstable angina pectoris, high-risk cerebrovascular abnormalities that have not been treated, etc.